Abrenica, Kianna O.
HRN: 22-65-93 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/03/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/03/2023
05/10/2023
IV
46mg
Q24
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes